In conclusion, epoxide hydrolase inhibitors, particularly those targeting sEH, represent a promising therapeutic approach for Alzheimer’s disease and other neurological disorders. The gene discussed is EPHX2; the disease is early-onset autosomal dominant Alzheimer disease.